newsfilter
← Earnings
Earnings Releases·

Prime Medicine — November 2026 Earnings Summary

  • Secured $108.8 million in cash and equivalents with runway extending into 2027, bolstered by an $110 million upfront payment from Bristol Myers Squibb (including $55 million equity) and up to $39 million in Cystic Fibrosis Foundation funding.
  • Pipeline milestones include anticipated initial clinical data for PM577a (Wilson Disease) and PM647 (AATD) in 2027, with a planned BLA submission for PM359 (Chronic Granulomatous Disease) in the first half of 2027.
  • Strategic collaboration with Bristol Myers Squibb targets ex vivo CAR-T products using PASSIGE technology, with potential milestone payments exceeding $3.5 billion and royalties on net sales.
  • Proprietary Prime Editing platform demonstrates safety advantages over CRISPR-Cas9 with no observed off-target edits or large deletions in lead programs, supported by a patent estate covering 10 U.S. and 21 ex-U.S. issued patents.
Company
PRIME MEDICINE INC
Sector
Healthcare
Industry
Biotechnology